Page last updated: 2024-10-27

gabapentin and Diffuse Parenchymal Lung Disease

gabapentin has been researched along with Diffuse Parenchymal Lung Disease in 1 studies

Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.
gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.

Research Excerpts

ExcerptRelevanceReference
"Gabapentin, a neurotransmitter modulator, is thought to treat refractory cough associated with interstitial lung disease by improving cough hypersensitivity."9.51The efficacy of gabapentin for the treatment of refractory cough associated with interstitial lung disease: study protocol for a randomized, double-blind and placebo-controlled clinical trial. ( Gao, R; Pu, J; Shi, C; Tang, J; Wang, S; Wang, X; Wen, S; Xu, X; Yu, L; Zhu, Y, 2022)
"Gabapentin, a neurotransmitter modulator, is thought to treat refractory cough associated with interstitial lung disease by improving cough hypersensitivity."5.51The efficacy of gabapentin for the treatment of refractory cough associated with interstitial lung disease: study protocol for a randomized, double-blind and placebo-controlled clinical trial. ( Gao, R; Pu, J; Shi, C; Tang, J; Wang, S; Wang, X; Wen, S; Xu, X; Yu, L; Zhu, Y, 2022)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Gao, R1
Xu, X1
Wang, S1
Pu, J1
Shi, C1
Wen, S1
Zhu, Y1
Tang, J1
Wang, X1
Yu, L1

Trials

1 trial available for gabapentin and Diffuse Parenchymal Lung Disease

ArticleYear
The efficacy of gabapentin for the treatment of refractory cough associated with interstitial lung disease: study protocol for a randomized, double-blind and placebo-controlled clinical trial.
    Trials, 2022, Feb-21, Volume: 23, Issue:1

    Topics: Cough; Double-Blind Method; Gabapentin; Humans; Lung Diseases, Interstitial; Prospective Studies; Qu

2022